Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Format: Artykuł
Język:English
Wydane: Korean Association for the Study of Intestinal Diseases 2022-01-01
Seria:Intestinal Research
Hasła przedmiotowe:
Dostęp online:http://irjournal.org/upload/pdf/ir-2020-00117.pdf